Signaturefd, LLC Allakos Inc. Transaction History

Signaturefd, LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 01, 2023	SELL	$3.6 - $5.25 $6,242 - $9,103	-1,734 Reduced 52.15%	1,591 $6,000
Q1 2023 Apr 28, 2023	SELL	$4.3 - $8.27 $2,898 - $5,573	-674 Reduced 16.85%	3,325 $14,000
Q4 2022 Jan 27, 2023	BUY	$5.66 - $8.42 $5,014 - $7,460	886 Added 28.46%	3,999 $33,000
Q3 2022 Nov 08, 2022	BUY	$3.02 - $6.12 $9,401 - $19,051	3,113 New	3,113 $19,000
Q2 2022 Aug 10, 2022	SELL	$2.6 - $6.14 $2,672 - $6,311	-1,028 Closed	0 $0
Q1 2022 May 02, 2022	BUY	$5.08 - $9.81 $4,572 - $8,829	900 Added 703.13%	1,028 $6,000
Q4 2021 Jan 25, 2022	BUY	$8.55 - $111.89 $846 - $11,077	99 Added 341.38%	128 $1,000
Q3 2021 Oct 28, 2021	SELL	$76.53 - $110.43 $76 - $110	-1 Reduced 3.33%	29 $3,000
Q2 2021 Jul 26, 2021	SELL	$85.37 - $114.1 $426 - $570	-5 Reduced 14.29%	30 $3,000
Q1 2021 Apr 30, 2021	BUY	$109.73 - $153.66 $877 - $1,229	8 Added 29.63%	35 $4,000
Q4 2020 Feb 11, 2021	SELL	$79.58 - $152.45 $477 - $914	-6 Reduced 18.18%	27 $4,000
Q2 2020 Jul 30, 2020	BUY	$44.04 - $80.69 $1,453 - $2,662	33 New	33 $2,000

66M

47.1K

Ticker ALLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,726,096
Market Cap $22M
Description
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...

Get notified when there are updates to the investment portfolio of Signaturefd, LLC, based on Form 13F filings with the SEC.

Stay updated on Signaturefd, LLC with notifications on news.